Assessment Status |
Awaiting response from Applicant |
HTA ID |
23029 |
Drug |
Olaparib |
Brand |
Lynparza® |
Indication |
Olaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with mCRPC in whom chemotherapy in not clinically indicated |
Rapid review commissioned |
31/05/2023 |
Rapid review completed |
13/06/2023 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with abiraterone and prednisone or prednisolone compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
28/06/2023 |
Pre-submission consultation with Applicant |
09/08/2023 |
Full submission received from Applicant |
31/01/2024 |
Preliminary review sent to Applicant |
21/11/2024 |